### **UTILITY PATENT APPLICATION TRANSMITTAL** (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. P-188

Total Pages in this Submission

#### TO THE ASSISTANT COMMISSIONER FOR PATENTS

**Box Patent Application** Washington, D.C. 20231

	for filing under 35 C	J.S.C. 111(a) ai	nd 37 C.F.R. 1.53	(b) is a new utility patent ap	oplication lesses
invention entitled:			AC 755	100 × 20	
Methods for Treatn	nent of Lupus Eryth	ematosus			5 0 0
and invented by:		· · · · ·			
Clark M. Whitehead	d, Keith A. Earle, H	ector W. Alila a	nd W. Joseph Tho	mpson	
f a CONTINUATION	APPLICATION, cf	neck appropriat	e box and supply	the requisite information:	
☐ Continuation	☐ Divisional	☐ Continuati	on-in-part (CIP)	of prior application No.:	
Which is a:					
☐ Continuation	□ Divisional	☐ Continuati	on-in-part (CIP)	of prior application No.:	
Which is a:					
☐ Continuation	☐ Divisional	☐ Continuati	on-in-part (CIP)	of prior application No.:	
Enclosed are:					
		Applica	tion Elements		
	as calculated and t	ransmitted as c	lescribed below		
2. 🛛 Specifica	ition having	59	pages and i	ncluding the following:	
a. 🗵 Desc	criptive Title of the I	nvention			
b. 🔲 Cros	ss References to Re	elated Application	ons (if applicable)		
c. 🔲 State	ement Regarding F	ederally-sponso	ored Research/De	velopment (if applicable)	
d. □ Refe	erence to Microfiche	Annendix <i>(if a)</i>	onlicable)		

g. 🛚 Brief Description of the Drawings (if drawings filed)

e. 🗵

f. 🗵

h. 🗵

**Detailed Description** i. 🛛 Claim(s) as Classified Below

Background of the Invention

Brief Summary of the Invention

Reference to Microfiche Appendix (if applicable)

j. 🛛 Abstract of the Disclosure

## UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. P-188

Total Pages in this Submission

	Application Elements (C ntinued)						
3.	$\boxtimes$	Drawing(s) (when necessary as prescribed by 35 USC 113)					
	a.	□ Formal					
4.	×	Oath or Declaration					
	a.	☑ Newly executed (original or copy)  ☐ Unexecuted					
	b.	☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)					
	C.	☑ With Power of Attorney ☐ Without Power of Attorney					
	d.	<ul> <li>DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).</li> </ul>					
5.		Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.					
6.		Computer Program in Microfiche					
· 7.		Genetic Sequence Submission (if applicable, all must be included)					
-	a.	□ Paper Copy					
:	b.	□ Computer Readable Copy					
	C.	□ Statement Verifying Identical Paper and Computer Readable Copy					
1		Accompanying Application Parts					
₹/8.	×	Assignment Papers (cover sheet & documents)					
9.	$\boxtimes$	37 CFR 3.73(b) Statement (when there is an assignee)					
10.		English Translation Document (if applicable)					
11.		Information Disclosure Statement/PTO-1449   Copies of IDS Citations					
12.		Preliminary Amendment					
13.	X	Acknowledgment postcard					
14.	×	Certificate of Mailing					
		☐ First Class ☒ Express Mail (Specify Label No.): EF360328485US					

# UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. P-188

Total Pages in this Submission

	Accompanying Application Parts (Continu d)				
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)			
16.		Small Entity Statement(s) - Specify Number of Statements Submitted:			
17.	X	Additional Enclosures (please identify below):			
		Petition to Accept Color Drawings under 37 C.F.R. § 1.84(2); Check in the amount of \$130.00 for the petition fee			
		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)			
18.		Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.			
		Warning			
		An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.			

## UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. P-188

Total Pages in this Submission

#### **Fee Calculation and Transmittal**

CLAIMS AS FILED						
For	#Filed	#Allowed	#Extra		Rate	Fee
Total Claims	39	- 20 =	19	х	\$9.00	\$171.00
indep. Claims	5	- 3 =	2	x	\$40.00	\$80.00
Multiple Dependent Cl	Multiple Dependent Claims (check if applicable)					\$0.00
BASIC FEE					\$355.00	
OTHER FEE (specify	OTHER FEE (specify purpose) \$0.00				\$0.00	
	TOTAL FILING FEE \$606.00					\$606.00
<ul> <li>A check in the amount of \$606.00 to cover the filing fee is enclosed.</li> <li>✓ The Commissioner is hereby authorized to charge and credit Deposit Account No. 500352 as described below. A duplicate copy of this sheet is enclosed.         <ul> <li>☐ Charge the amount of as filing fee.</li> <li>☑ Credit any overpayment.</li> <li>☑ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.</li> <li>☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).</li> </ul> </li> <li>Dated: August 23, 2001</li> </ul>						

CC:

Cell Pathways, Inc. 702 Electronic Drive Horsham, PA 19044

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Clark M. Whitehead et al.	)
For: Methods for Treatment of Lupus Erythematosus	)

### **CERTIFICATE OF MAILING**

I certify that the following were deposited with the U.S. Postal Service "Express Mail No. EF360328485US to Addressee" service under 37 C.F.R. § 1.10 on the date indicated below and was addressed to the Assistant Commissioner for Patents, Washington D.C., 20231:

- 1. Patent Application Transmittal Letter (in duplicate);
- 2. Patent Application entitled "Methods for Treatment of Lupus Erythematosus" (59 pages with 13 sheets of drawings);
- 3. Declaration and Power of Attorney;
- 4. Check in the amount of \$606.00 for filing fees;
- 5. Recordation of Assignment form;
- 6. Assignment;
- 7. Check in the amount of \$40.00 for the assignment fee;
- 8. Statement Under 37 CFR 3.73(b);
- 9. Verified Statement Claiming Small Entity Status; (37 CFR 1.9 (f) and 1.27 (c);
- 10. Petition to Accept Color Drawings;
- 11. Check in the amount of \$130.00 for the petition fee;
- 12. Certificate of Mailing;
- 13. Acknowledgement Postcard.

Date: <u>August 23, 2001</u>

Send all correspondence to: Robert W. Stevenson

Cell Pathways, Inc. 702 Electronic Drive Horsham, PA 19044 (215) 706-3800